Additional Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
- Conditions
- Rectal Cancer
- Registration Number
- NCT01671683
- Lead Sponsor
- Chungnam National University
- Brief Summary
The aim of this study is to evaluate the efficacy and safety of additional neoadjuvant chemotherapy with capecitabine during the resting periods in patients with locally advanced rectal cancer.
- Detailed Description
Neoadjuvant chemoradiotherapy (NCRT) has been used as standard treatment modality in patients with locally advanced rectal cancer (LARC) because of increased local control, enhanced sphincter preservation, and less toxicity.NCRT has enhanced down-staging of tumor and reduced local recurrence. However, survival benefit of NCRT has not been demonstrated and the rate of distant metastasis was still reported as high as 30%.
Patients with pathologic complete remission (pCR) after NCRT have shown excellent survival benefit. We inferred that additional chemotherapy during the resting period could enhance the pCR rate. The aim of the present study is to evaluate the safety and efficacy of an additional 4-week chemotherapy with capecitabine after the conventional 6-week NCRT in patients with LARC.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 44
- histologically proven, locally advanced adenocarcinoma of the rectum
- an Eastern Cooperative Oncology Group (ECOG) score of 0-2
- adequate function of major organs
- a signed informed consent.
- other co-existing malignancy or malignancy within the last 5 years prior to enrollment
- severe concurrent medical or psychiatric disorders
- prior RT to pelvis
- pregnant or lactating patients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Republic of